POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
Did Not Advance

Arizona HB 4036 Restricts Compounded Weight-Loss Drugs and Imposes Sourcing and Testing Rules

Original title: bulk drug substances; prohibitions

Last action · February 18, 2026: FAILEDSponsor: Michele Peña

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Proposed

Arizona HB 4036 would prohibit the sale or distribution of compounded weight-loss medications—specifically those using GLP-1 or GIP receptor agonists—unless compounders and suppliers meet strict federal registration, quality testing, inspection, and record-keeping requirements. The bill establishes civil penalties of $1,000 per dose for violations, authorizes state board inspections, and bans deceptive advertising for compounded drugs.

Why it matters

The measure establishes new state-level oversight and $1,000-per-dose penalties for compounding pharmacies, wholesalers, and advertisers handling specific weight-loss and obesity medications, directly altering compliance obligations and supply-chain documentation rules in Arizona.

Background
  • Compounded medications are customized drugs created by pharmacists to meet specific patient needs when commercially available products are unsuitable or unavailable. context
  • GLP-1 receptor agonist medications have experienced soaring demand for weight management, leading to increased federal and state scrutiny over the safety of compounded alternatives. context

Who It Would Have Affected

Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.

Directly affected

Compounding Pharmacies

Compounding pharmacies must comply with strict bulk drug sourcing standards, conduct pre-use and finished batch testing, maintain records for two years post-expiration, and adhere to new advertising restrictions.

Directly affected

Drug Manufacturers and Wholesalers

Manufacturers and wholesalers selling bulk drug substances in Arizona for compounding must provide written verification of pharmaceutical-grade quality, testing documentation, and certificates of analysis.

Directly affected

State Board of Pharmacy

The Board is granted explicit authority to inspect compounding facilities, domestic suppliers, and wholesalers, request records, and adopt implementation rules.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What types of drugs are targeted by the new restrictions in HB 4036?
The bill specifically targets s that use glucose-dependent insulinotropic polypeptide receptor or s used for obesity or weight management.
What documentation must suppliers provide to compounding pharmacies?
Manufacturers and wholesalers must provide written verification that the is pharmaceutical grade and meets sourcing requirements, along with documentation of quality control testing and a valid .
What penalties can be applied for violating these compounding rules?
Violators may face a civil penalty of $1,000 per dose of the illegally compounded drug sold, transferred, or distributed, as well as suspension or revocation of their license or permit.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

This bill did not become law - Failed in the House.

Procedural history

4 actions
  1. Feb 18, 2026HouseFloor
    FAILED
  2. Feb 11, 2026House
    W/D
  3. Feb 10, 2026HouseFloor
    House Second Reading
  4. Feb 9, 2026HouseIntroduced
    House First Reading

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Connected Entities

United States Food and Drug Administration, Michele Peña, State Board of Pharmacy
OrganizationUnited States Food and Drug Administration“Federal agency responsible for drug approvals, facility registrations, and inspe”Map →
PersonMichele Peña“Representative introducing HB 4036 in the Arizona House of Representatives”Map →
OrganizationState Board of Pharmacy“Arizona state board granted inspection and record request authority under the bi”Map →

Sources

Open source document

apps.azleg.gov

Analysis Score

0–100
  • Significance20
    Lowered because this bill did not pass (its text scored 75)
  • Controversy65
    Intensity of disagreement among stakeholders
  • Entertainment20
    Compellingness for a non-policy-wonk reader
  • Buzz50
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record